Kestra Medical Technologies, Ltd.
NASDAQ:KMTSMedical - Instruments & Supplies
-$0.07 today
- Market cap
- $1.69B
- Beta
- 0.83
- P/E (TTM)
- -6.9
- EPS (TTM)
- -$2.74
Volume 0.44M
Average 0.33M
KMTS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Kestra Medical Technologies, Ltd.NASDAQ: KMTS
Revenue · Q3 FY2026 · quarter ended Jan 2026
Revenue growth accelerates
Q3 FY2026 revenue of $24.55M rose 62.7% year over year, ahead of the +59.1% change in trailing-twelve-month revenue. Sequentially, it rose 8.8% from the prior quarter.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $92.97M (+55.4%) for the fiscal year ending Apr 2026, a slowdown from the +115.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJan 2026
- $24.55M+8.8% QoQ
- Last fiscal yearApr 2025
- $59.82M+115.1% YoY
- LTMJan 2026
- $83.72M+59.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +62.7% | +53.7% | -9.0 pp |
| 1 year | +115.1% | +55.4% | -59.6 pp |
| 3-year CAGR | — | +48.5% | — |
| 5-year CAGR | +41.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 59.82M USD
- Year-over-year change
- +115.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 59.82M | +115.1% |
| FY2024 | 2024-04-30 | 27.81M | +264.5% |
| FY2023 | 2023-04-30 | 7.63M | — |
| FY2021 | 2021-04-30 | 0 | — |
| FY2020 | 2020-04-30 | 0 | — |
Revenue vs competitors
How KMTS compares with its peers on the latest reported figures
- KMTS's LTM Jan 2026 revenue of $83.72M is the 2nd highest of the 3 companies compared; the peer median is $456.56M.
- Its year-over-year change of +59.1% is the highest of 3, against a peer median of +16.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $854.04M | +21.6% | +22.1% | |
| LTM Jan 2026 | $83.72M | +59.1% | — | |
| LTM Mar 2026 | $59.07M | +11.7% | +36.1% | |
| Peer median (excluding KMTS) | $456.56M | +16.6% | +29.1% | |
Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2020 Apr 2020 | FY2021 Apr 2021 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.63M | 27.81M | 59.82M |
| Cost of Revenue | 0 | 0 | 18.28M | 27.45M | 35.61M |
| Gross Profit | 0 | 0 | (10.65M) | 362K | 24.21M |
| Gross Margin | — | — | -139.6% | 1.3% | 40.5% |
| Research & Development | 22.8M | 18.81M | 15.76M | 15.49M | 15.65M |
| Selling, General & Admin | 6.52M | 13.9M | 54.01M | 69.94M | 114.94M |
| Operating Expenses | 29.32M | 32.71M | 69.77M | 85.43M | 130.59M |
| Depreciation & Amortization | 478K | 420K | 4.86M | 11.56M | 7.97M |
| EBITDA | (28.84M) | (32.33M) | (73.74M) | (76.31M) | (97.98M) |
| EBITDA Margin | — | — | -966.4% | -274.3% | -163.8% |
| Operating Income | (29.32M) | (32.71M) | (80.42M) | (85.06M) | (106.38M) |
| Operating Margin | — | — | -1054.0% | -305.8% | -177.8% |
| Interest Income | 0 | 0 | 0 | 0 | 3.2M |
| Interest Expense | 0 | 1.17M | 5.63M | 6.23M | 7.73M |
| Other Income / Expenses | 0 | (1.21M) | (3.8M) | (9.03M) | (7.3M) |
| Income Before Tax | (29.32M) | (33.91M) | (84.22M) | (94.1M) | (113.68M) |
| Pre-Tax Margin | — | — | -1103.8% | -338.3% | -190.1% |
| Income Tax Expense | 148K | 187K | 15K | 24K | 135K |
| Net Income | (29.47M) | (34.1M) | (84.24M) | (94.12M) | (113.81M) |
| Net Margin | — | — | -1104.0% | -338.4% | -190.3% |
| EPS (Basic) | (0.59) | (0.69) | (1.75) | (2.04) | (5.13) |
| EPS (Diluted) | (0.59) | (0.69) | (1.75) | (2.04) | (5.13) |
| Weighted Avg Shares | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M |
| Weighted Avg Shares (Diluted) | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M |
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
Intrinsic Alpha fair value
Locked
Current Price
$28.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.